S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer
Randomized Phase III Trial of Cisplatin and Irinotecan (NSC-616348) Versus Cisplatin and Etoposide in Patients With Extensive Stage Small Cell Lung Cancer (E-SCLC)
Sponsor: Cancer and Leukemia Group B
This PHASE3 trial investigates Lung Cancer and is currently completed. Cancer and Leukemia Group B leads this study, which shows 9 recorded versions since 2002 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
May 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — May 2023 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Aug 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Aug 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Nov 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cancer and Leukemia Group B
- National Cancer Institute (NCI)
- North Central Cancer Treatment Group
- SWOG Cancer Research Network
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adrian, United States, Akron, United States, Alexandria, United States, Allentown, United States, Alton, United States, American Fork, United States, Anchorage, United States, Anderson, United States, Ann Arbor, United States, Anniston, United States and 253 more location s